Combination Antibiotic-Steroid for Ocular Inflammation Filed for FDA Approval
ISTA Pharmaceuticals Inc., which develops eye-care treatments said Thursday it filed a new drug application with the U.S. Food and Drug Administration for its combination antibiotic steroid to fight ocular inflammation.
The topical product, called T-Pred, is a combination of tobramycin and prednisolone acetate.
The company finished a Phase III clinical trial of the treatment candidate during the fourth quarter of 2005. ISTA expects to launch the drug in mid-2007 if it is approved.
Filed under Eye Treatment |
You may also like to read
- Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular Pressure
- Antibiotic Fights Lymphoma of Eye Linked to Chlamydia
- Antibiotics Alone No Match for Blinding Eye Infection Trachoma
- Mysterious Post Operative Eye Infection (TASS) Swept Across the Continent
- Single Mass Antibiotic Treatment Is Not Enough To Treat And Eliminate Trachoma
- Dry Eye Treatment by Omega Fatty Acids in Combination with Artificial Tears
- Alcon Gets FDA Approval for Travatan-Z Which Reduce Elevated Intraocular Pressure
- Beware of Sandoz Prednisolone 1% Ophthalmic Suspension due to potential health risk
- Reappearance of Inturned Eyelashes May be Prevented by Azithromycin
- Pfizer Antibiotic Zithromax for Eye Infection May Bring Re-Infections
